Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fibromyalgia | 9 | 2019 | 31 | 1.750 |
Why?
|
| Cognition Disorders | 2 | 2015 | 1055 | 0.450 |
Why?
|
| Attention | 2 | 2015 | 145 | 0.350 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 1133 | 0.290 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2016 | 365 | 0.280 |
Why?
|
| Citrulline | 2 | 2016 | 12 | 0.270 |
Why?
|
| Cognition | 1 | 2015 | 1427 | 0.260 |
Why?
|
| Aggrecans | 2 | 2016 | 157 | 0.250 |
Why?
|
| Memory, Short-Term | 1 | 2006 | 104 | 0.250 |
Why?
|
| Brain | 1 | 2015 | 1800 | 0.240 |
Why?
|
| Memory Disorders | 1 | 2006 | 177 | 0.230 |
Why?
|
| Arthritis, Experimental | 2 | 2016 | 132 | 0.220 |
Why?
|
| Rheumatology | 4 | 2019 | 90 | 0.220 |
Why?
|
| Pain Measurement | 2 | 2019 | 489 | 0.170 |
Why?
|
| Epitopes | 2 | 2016 | 88 | 0.170 |
Why?
|
| Symptom Assessment | 2 | 2016 | 23 | 0.160 |
Why?
|
| Chronic Pain | 1 | 2019 | 111 | 0.150 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2010 | 221 | 0.140 |
Why?
|
| Self Report | 2 | 2016 | 231 | 0.140 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 1316 | 0.140 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 15 | 0.130 |
Why?
|
| Humans | 16 | 2019 | 30959 | 0.130 |
Why?
|
| Prognosis | 3 | 2015 | 919 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 549 | 0.130 |
Why?
|
| Patient Participation | 1 | 2016 | 53 | 0.130 |
Why?
|
| Proteoglycans | 1 | 2016 | 345 | 0.120 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 43 | 0.120 |
Why?
|
| Female | 11 | 2019 | 16965 | 0.110 |
Why?
|
| Prevalence | 1 | 2015 | 500 | 0.110 |
Why?
|
| Memory | 1 | 2015 | 328 | 0.110 |
Why?
|
| Male | 10 | 2019 | 16425 | 0.100 |
Why?
|
| Quality of Life | 2 | 2015 | 697 | 0.100 |
Why?
|
| Cartilage, Articular | 1 | 2016 | 550 | 0.090 |
Why?
|
| Hydrazines | 1 | 2010 | 8 | 0.090 |
Why?
|
| Benzoates | 1 | 2010 | 7 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2010 | 54 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 1210 | 0.080 |
Why?
|
| Adult | 6 | 2016 | 8924 | 0.080 |
Why?
|
| Plasmapheresis | 1 | 2007 | 14 | 0.070 |
Why?
|
| Middle Aged | 7 | 2019 | 10192 | 0.070 |
Why?
|
| Lupus Nephritis | 1 | 2007 | 30 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2019 | 353 | 0.070 |
Why?
|
| Data Collection | 1 | 2006 | 109 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2016 | 89 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2016 | 204 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2016 | 178 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2016 | 660 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2016 | 204 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 223 | 0.060 |
Why?
|
| Frail Elderly | 1 | 2002 | 52 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 583 | 0.050 |
Why?
|
| Mice | 2 | 2016 | 1683 | 0.040 |
Why?
|
| Remission Induction | 2 | 2010 | 105 | 0.040 |
Why?
|
| Exercise | 1 | 2002 | 507 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 1897 | 0.040 |
Why?
|
| Spleen | 1 | 2016 | 55 | 0.030 |
Why?
|
| Aged | 4 | 2015 | 10047 | 0.030 |
Why?
|
| Complex Mixtures | 1 | 2016 | 4 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 135 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 194 | 0.030 |
Why?
|
| Tissue Extracts | 1 | 2016 | 12 | 0.030 |
Why?
|
| Arginine | 1 | 2016 | 19 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2016 | 54 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2016 | 63 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2016 | 68 | 0.030 |
Why?
|
| Animals | 2 | 2016 | 4722 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 430 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 191 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2016 | 686 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2014 | 14 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 351 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 1922 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 817 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 344 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2013 | 4 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 51 | 0.030 |
Why?
|
| Histones | 1 | 2013 | 28 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 158 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 164 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 333 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 57 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 270 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 78 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 5189 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 164 | 0.030 |
Why?
|
| Piperazines | 1 | 2013 | 91 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2013 | 176 | 0.030 |
Why?
|
| Gene Expression | 1 | 2013 | 238 | 0.030 |
Why?
|
| Apoptosis | 1 | 2013 | 260 | 0.020 |
Why?
|
| Osteoarthritis | 1 | 2016 | 384 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2010 | 3 | 0.020 |
Why?
|
| Molecular Mimicry | 1 | 2010 | 5 | 0.020 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2010 | 4 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 2010 | 9 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2010 | 27 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2010 | 51 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2010 | 3806 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 782 | 0.020 |
Why?
|
| United States | 1 | 2016 | 2373 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 508 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 785 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 320 | 0.020 |
Why?
|
| Biopsy | 1 | 2007 | 249 | 0.020 |
Why?
|
| Kidney | 1 | 2007 | 181 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 161 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 2042 | 0.020 |
Why?
|
| Physical Education and Training | 1 | 2002 | 4 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2002 | 51 | 0.010 |
Why?
|
| Exercise Test | 1 | 2002 | 128 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2002 | 198 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2002 | 429 | 0.010 |
Why?
|